ALDARA
LOE ApproachingNDATOPICALCREAM
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDARA is a topical cream containing imiquimod, an immune response modifier that activates toll-like receptors to stimulate local and systemic immune responses. It is approved for genital warts and colorectal cancer, representing a unique immunotherapeutic approach to dermatologic and oncologic conditions. The drug works by enhancing innate and adaptive immunity at the site of application.
LOE Approaching
Product is approaching loss of exclusivity with minimal commercial team expansion; focus shifting toward lifecycle management and preparation for generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
H5N1 With or Without Topical Aldara in Healthy Adults
Started Jun 2018
50 enrolled
Avian InfluenzaInfluenza Immunisation
Why This Matters for Your Career
Worked on ALDARA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.